We believe our approach can extend beyond CD33 to other potential target candidates for our eHSCs and CAR-T therapies.
We believe our approach shows significant promise when potential targets fulfill three important criteria:
Discovery Platform
Vor Bio is researching additional cell surface targets in the fight against cancer
1
These targets are expressed on cancer cells
2
These targets are expressed on cells of hematopoietic lineage
3
There is evidence these protein targets are biologically dispensable
We have generated data exploring targets such as CD123, CLL-1, and EMR2 which all currently show promise fulfilling these criteria.
Other Myeloid Targets: CD123, CLL-1, and EMR2
CD123, CLL-1, and EMR2 are targets expressed strongly in various myeloid blood cancers including AML. These targets are expressed both in bulk AML cells as well as leukemic stem cells. Our preclinical data demonstrates our ability to genetically engineer HSCs in human cells to remove expression of these targets with good efficiency. As such, we continue to research CD123, CLL-1, and EMR2 as potential target candidates for our shielded transplants and CAR-T therapies.
Related Publications
Filter by:
Clear all filters
Search Publications
Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to treat AML
Analyzing Guide RNA (gRNA) Impurity Discovery & Quantification
Purification of CAR+ T Cells Reveals Impact of Untransduced Cells in CAR-T Drug Product
Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML
Uncovering Molecular and Functional Dynamics of Human Hematopoietic Stem Cells during In Vitro Culture for Cell Therapy Manufacturing
Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to target AML
CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies
Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens